September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
FDA Accepts Daprodustat NDA for Anemia of Chronic Kidney Disease
The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.
Finerenone Consistently Reduced Cardiorenal Risk Regardless of ASCVD History in FIDELITY
In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.
New Diabetes Device Comparison Platform Supports Clinical Decision-making, Prescribing
DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.
Diabetes Technology Myths & Facts for Primary Care Practitioners
Initiating diabetes technology of any kind is a big step for patients, but also for a lot of primary care clinicians. If you have concerns, these myths and facts are for you.
Sotagliflozin Reduced MACE Risk in Patients With and Without Prior CVD, in New Analysis of SCORED Clinical Trial
ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.
FDA Approves Higher Dose of Semaglutide (2 mg) to Reduce HbA1c in Type 2 Diabetes
The higher dose of the GLP-1 analogue allows more flexibility for patients with T2D needing to intensify treatment, says manufacturer Novo Nordisk.
Bodyweight Variability May Increase Risk for Major CV Events in Type 2 Diabetes Patients: New Study
Persons with type 2 diabetes who either gained or lost 5% of baseline bodyweight were found to be at higher risk for heart failure, MI, and all-cause death.
Empagliflozin CKD Phase 3 Trial Stopped Early for Positive Efficacy Seen in Interim Assessment
The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.
Moderate Wine Intake with Food May Help Decrease T2D Risk in Adults
Moderate consumption of alcohol with food was significantly associated with a 14% lower risk of type 2 diabetes in a preliminary analysis.
CGM-measured Glucose Variability Associated with Diabetes Micro- and Macrovascular Complications
Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.
FDA Grants Empagliflozin Broad Heart Failure Indication
The landmark approval for the SGLT-2 inhibitor will open access to treatment for the ~ 3 million adults with heart failure with preserved ejection fraction.
FDA Grants Clearance to First Smartphone App for Programming Insulin Dosing
t:slim X2 insulin pump users can now program or cancel bolus dosing with the secure t:connect mobile app already on their phones, says Tandem Diabetes Care.
In Patients with T2D and ASCVD, Prescriptions for Evidence-based Therapies Far from Adequate
US patients at high CV risk do not receive adequate evidence-based pharmacotherapy, according to large multisite cohort analysis.
Diabetes Care & Education Specialists, ADA Update National Standards for Diabetes Self-management Education and Support
The 2022 DSMES National Standards update focuses on reducing administrative burden on educators and improving person-centered care for patients.
FDA Approves Eversense E3 CGM System for Use up to 6 Months
The 180-day sensor life doubles the period of continuous use and cuts in half the number of CGM removals and reinsertions, without loss of accuracy.
Obesity Common Among Adults Aged <50 Years with Acute Ischemic Stroke, Study Finds
Nearly two-thirds of persons aged younger than 50 years who had an acute ischemic stroke had obesity in a study presented at the 2022 International Stroke Conference.
Risk for Diabetes in Older Women Reduced by 12% with 2000 Steps per Day: Study
Higher daily step counts by women aged ≥65 years was associated with reduced risk for incident diabetes, an effect that was modified by the level of stepping intensity.
Blood Glucose Levels in T2D: 42 Factors that Make A Difference
These 42 factors that affect blood glucose are listed in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.
Tirzepatide Found Safe, Effective as Add-on to Stable Basal Insulin in T2D Patients Not at Goal
Tirzepatide at 3 different doses significantly improved glycemic control and promoted weight loss when added to titrated insulin in patients with type 2 diabetes.
SGLT-2 Inhibitors and GLP-1 RAs May Reduce NAFLD Risk in T2D
Use of SGLT2 inhibitor and GLP-1 RA therapy in patients with type 2 diabetes appears to confer hepatic protection when compared with use of DPP-4 inhibitors.
Real Time CGM Improves A1c, Time in Range in T2D Patients on Less Intensive Treatment
Greatest improvements in A1c, %TIR, and other glycemic parameters were seen in patients treated with ≤1 medication, in another challenge to current payer restrictions.
Call for a NAFLD Care Pathway in T2D in Primary Care
Integrating NAFLD as a diabetes complication to be addressed during routine cycles of care could reduce barriers to a NAFLD pathway in primary care, agreed focus group participants.
Sleep Duration May Have Greater Cardiometabolic Impact on Women vs Men
Results of a new study that used early clinical surrogate markers of metabolic disease find women at greater risk related to suboptimal sleep.
Painful Diabetic Neuropathy Treatment: A Guideline Topline
The American Academy of Neurology recently issued a guideline on oral and topical treatments for painful diabetic neuropathy. Here, a concise summary for clinicians.
Blood Glucose Down, Insulin Sensitivity Up with 10 Minutes of Moderate-intensity Stair Stepping
Glucose and insulin levels decreased after just 3 minutes of the moderate-intensity exercise, a promising finding for those with type 2 diabetes, say authors of a new study.
CHD Prevalence in US Shows No Significant Change, According to BRFSS Analysis
Coronary heart disease prevalence in the US between 2011 and 2018 saw a statistically insignificant change, from 6.2% to 6.0%, respectively.
CGM-derived Time in Range Found Similar to A1c for Predicting Microvascular Complications in T2D
Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.
Less than 1 in 5 US Adults Meeting Heart Health Goals, According to AHA Scientific Statement
Available therapies combined with new approaches that address social determinants of health and other barriers to care can help, suggests new statement.
Obesity Expert Highlights 2021 Research Success, Looks to 2022 and Beyond
WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.
American Diabetes Association Publishes Standards of Medical Care for 2022
The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.